Show
Sort by
-
Challenges in neoantigen-directed therapeutics
-
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
-
- Journal Article
- A1
- open access
Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
-
Vegf-A mRNA transfection as a novel approach to improve mouse and human islet graft revascularisation
-
Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety
-
Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab
-
- Journal Article
- A1
- open access
Current status and perspectives of immune-based therapies for hepatocellular carcinoma
-
- Journal Article
- A2
- open access
Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon
-
- Journal Article
- A1
- open access
The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
-
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells